LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

LLY

901.29

-0.96%↓

JNJ

235.03

-0.28%↓

ABBV

204.68

-0.16%↓

NVS

148.56

+0.66%↑

AZN

185.31

+0.58%↑

Home・Elenco Azioni・Cogent Biosciences Inc

Cogent Biosciences Inc

Chiusa

34.93 -1.38

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

33.93

Massimo

35.42

Metriche Chiave
By Trading Economics
Entrata	-22M -102M
EPS	-0.5
Dipendenti	258
EBITDA	-30M -109M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+57.43% upside

Dividendi
By Dow Jones
Utili prossimi	5 mag 2026

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	184M 5.8B
Apertura precedente	36.31
Chiusura precedente	34.93

Punteggio Tecnico

By Trading Central

Fiducia

Bearish Evidence

4.88 / 5.87 Supporto e resistenza

Cogent Biosciences Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

23 mar 2026, 23:47 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets -- Update

23 mar 2026, 22:55 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion

23 mar 2026, 21:51 UTC

Acquisizioni, Fusioni, Takeovers

Italy's Postal Service Makes $12.50 Billion Bid for Telecom Italia -- 3rd Update

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Global Equities Roundup: Market Talk

23 mar 2026, 23:59 UTC

Discorsi di Mercato

Woodside, Santos Earnings Power Up on Surging LNG Prices -- Market Talk

23 mar 2026, 23:50 UTC

Discorsi di Mercato

Nikkei May Rise on Hopes for U.S. Talks With Iran -- Market Talk

23 mar 2026, 23:37 UTC

Discorsi di Mercato

Gold Rises, Boosted by Fall in Dollar, U.S. Treasury Yields -- Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Global Equities Roundup: Market Talk

23 mar 2026, 22:42 UTC

Discorsi di Mercato

Principali Notizie su Eventi

Bell Potter Names Miners Less Exposed to Fuel Price, Supply Risks -- Market Talk

23 mar 2026, 22:40 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for Up to $2.18B

23 mar 2026, 22:23 UTC

Discorsi di Mercato

Apollo Debt Solutions Shrugs Off Private-Credit Fears -- Market Talk

23 mar 2026, 22:22 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: OM336 Is for Treatment of Autoantibodies Driven Immune-Mediated Disease

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Pay Galapagos Royalties of 20%-23% of Net OM336 Sales

23 mar 2026, 22:21 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company Would Retain Sole Worldwide Commercialization Rights of OM336 Outside of Greater China

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Company, Galapagos Would Collaborate on Development of OM336 >GILD

23 mar 2026, 22:20 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Absorb Substantially All of Ouro's Operating Assets, Retain Its Employees >GILD

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Galapagos Would Pay 50% of Upfront Consideration and 50% of Any Contingent Milestone Payments Payable to Ouro Shareholders

23 mar 2026, 22:19 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences: Currently in Advanced Discussions With Galapagos With Respect to Potential Research-and-Development Collaboration on Acquired Ouro Assets

23 mar 2026, 22:18 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences to Buy Ouro Medicines for About $1.68B Upfront, Up to $500M in Contingent Milestone Payments >GILD

23 mar 2026, 22:15 UTC

Acquisizioni, Fusioni, Takeovers

Gilead Sciences To Acquire Ouro Medicines To Advance First In Class T Cell Engager Program For Autoimmune Diseases >GILD

23 mar 2026, 22:08 UTC

Discorsi di Mercato

Ebos Needs to Reset Its Gearing Targets -- Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

Global Forex and Fixed Income Roundup: Market Talk

23 mar 2026, 21:42 UTC

Discorsi di Mercato

RBNZ's Breman Strikes Reassuring Tone On Rates -- Market Talk

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman: Results Aided by Strong Growth in Contract Research, Development and Manufacturing Organisation Business>2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Net CNY1.56B Vs. Net CNY917.16M >2268.HK

23 mar 2026, 21:32 UTC

Utili

WuXi XDC Cayman 2025 Rev CNY5.94B Vs. CNY4.05B >2268.HK

23 mar 2026, 21:10 UTC

Principali Notizie su Eventi

Oil Is Back Under $100. Trump Says Iran Has Agreed to No Nuclear Weapons. -- Barrons.com

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Tech, Media & Telecom Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Health Care Roundup: Market Talk

23 mar 2026, 20:50 UTC

Discorsi di Mercato

Utili

Principali Notizie su Eventi

Basic Materials Roundup: Market Talk

Confronto tra pari

Modifica del prezzo

Cogent Biosciences Inc Previsione

Obiettivo di Prezzo

By TipRanks

57.43% in crescita

Previsioni per 12 mesi

Media 52.55 USD 57.43%

Alto 64 USD

Basso 35 USD

Basato su 12 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

12 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 12 che hanno fornito valutazioni azionarie a Cogent Biosciences Inc - Dist negli ultimi 3 mesi.

Punteggio Tecnico

By Trading Central

4.88 / 5.87Supporto e resistenza

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

All events are bearish.

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Cogent Biosciences Inc

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.